BRNS

News

prnewswire.comAre KW, BRNS, AFBI Obtaining Fair Deals for their Shareholders?prnewswire.comMay 12

businesswire.comBarinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNSbusinesswire.comMay 11

globenewswire.comBarinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developmentsglobenewswire.comApr 30

Trade BRNS

About Barinthus Biotherapeutics plc

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical firm, is dedicated to pioneering innovative T-cell immunotherapies. These cutting-edge treatments are engineered to harness the body's own immune system to effectively combat chronic infectious diseases, autoimmune disorders, and various cancers. The company is actively progressing a robust portfolio of experimental medicines spanning diverse medical fields. Prominent among these is VTP-300, an immunotherapeutic candidate striving to achieve a functional cure for chronic Hepatitis B virus (HBV) infection. Also in development is VTP-200, a non-surgical therapeutic option aimed at persistent high-risk human papillomavirus (HPV). For autoimmune conditions, VTP-1000 is an autoimmune candidate leveraging the proprietary SNAP-TI platform to treat celiac disease. Additionally, VTP-850 is a next-generation immunotherapeutic designed to address recurrent prostate cancer. Furthermore, the preclinical candidate VTP-1100 utilizes the SNAP-CI platform in its development as a potential treatment for HPV-related cancers. Originally established in 2016 under the name Vaccitech plc, the company rebranded to Barinthus Biotherapeutics plc in November 2023. Its main office is located in Harwell, United Kingdom.

CEO: William James Enright
IPO Date: Apr 30, 2021

Market Data

Open: $0.70
High: $0.70
Low: $0.6621
Volume: 9.7K
Avg Volume: 69K
52W High: $2.92
52W Low: $0.512

Valuation

Market Cap: $27M
Enterprise Value: $-29M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-48M
Revenue: $0
Net Income: $-67M
Cash: $70M
Debt: $11M

Events

EarningsAug 6

EPS est. -0.28